These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 8563472

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.
    Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M.
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):425-32. PubMed ID: 7955453
    [Abstract] [Full Text] [Related]

  • 3. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B, Puavilai G, Rajatanavin R.
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [Abstract] [Full Text] [Related]

  • 4. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH, Chen JF, Yang BY, Liu RT, Tung SC, Chien WY, Lu YC, Kuo MC, Hsieh CJ, Wang PW.
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.
    Duan Y, Tabensky A, DeLuca V, Seeman E.
    Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739
    [Abstract] [Full Text] [Related]

  • 7. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C, Golia F, Vignali E, Pinchera A.
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T, Nery L, Hales I.
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [Abstract] [Full Text] [Related]

  • 10. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T, Vehmanen L, Elomaa I, Välimäki M, Mäkelä P, Blomqvist C.
    Br J Cancer; 2001 Apr 20; 84(8):1047-51. PubMed ID: 11308252
    [Abstract] [Full Text] [Related]

  • 11. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
    De Rosa G, Testa A, Maussier ML, Callà C, Astazi P, Albanese C.
    Horm Metab Res; 1995 Nov 20; 27(11):503-7. PubMed ID: 8770627
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY, Weetman AP, Eastell R.
    Clin Endocrinol (Oxf); 1997 Mar 20; 46(3):301-7. PubMed ID: 9156039
    [Abstract] [Full Text] [Related]

  • 13. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
    Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A.
    J Clin Endocrinol Metab; 1994 Apr 20; 78(4):818-23. PubMed ID: 8157704
    [Abstract] [Full Text] [Related]

  • 14. Effects on bone mass after eight years of hormonal replacement therapy.
    Eiken P, Nielsen SP, Kolthoff N.
    Br J Obstet Gynaecol; 1997 Jun 20; 104(6):702-7. PubMed ID: 9197874
    [Abstract] [Full Text] [Related]

  • 15. Differential effects of hormone replacement therapy on bone mineral density and axial transmission ultrasound measurements in cortical bone.
    Knapp KM, Blake GM, Spector TD, Fogelman I.
    Osteoporos Int; 2003 Jun 20; 14(4):289-94. PubMed ID: 12730793
    [Abstract] [Full Text] [Related]

  • 16. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S.
    Osteoporos Int; 1998 Jun 20; 8(1):32-8. PubMed ID: 9692075
    [Abstract] [Full Text] [Related]

  • 17. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB, Noyan V, Yildiz A, Biberoğlu K.
    Climacteric; 2000 Jun 20; 3(2):92-101. PubMed ID: 11910657
    [Abstract] [Full Text] [Related]

  • 18. Dietary iron positively influences bone mineral density in postmenopausal women on hormone replacement therapy.
    Maurer J, Harris MM, Stanford VA, Lohman TG, Cussler E, Going SB, Houtkooper LB.
    J Nutr; 2005 Apr 20; 135(4):863-9. PubMed ID: 15795448
    [Abstract] [Full Text] [Related]

  • 19. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J.
    J Bone Miner Res; 1999 Sep 20; 14(9):1583-95. PubMed ID: 10469288
    [Abstract] [Full Text] [Related]

  • 20. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
    De Rosa G, Testa A, Giacomini D, Carrozza C, Astazi P, Caradonna P.
    Clin Endocrinol (Oxf); 1997 Nov 20; 47(5):529-35. PubMed ID: 9425392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.